Jefferies Financial Group Inc. Acquires New Shares in Collegium Pharmaceutical, Inc. $COLL

Jefferies Financial Group Inc. purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 27,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $992,000. Jefferies Financial Group Inc. owned approximately 0.08% of Collegium Pharmaceutical as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Collegium Pharmaceutical in the second quarter worth about $196,972,000. Jupiter Topco LLC bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth about $77,743,000. Janus Henderson Group PLC grew its stake in Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares during the last quarter. Millennium Management LLC grew its position in Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Collegium Pharmaceutical in the second quarter valued at $9,882,000.

Wall Street Analysts Forecast Growth

COLL has been the subject of several recent research reports. Needham & Company LLC dropped their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wall Street Zen downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $25.35 on Monday. The company’s 50 day moving average price is $32.96 and its two-hundred day moving average price is $34.98. Collegium Pharmaceutical, Inc. has a 12-month low of $25.16 and a 12-month high of $50.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The firm has a market cap of $825.40 million, a PE ratio of 20.44 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The business had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same quarter last year, the business posted $1.68 EPS. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.